Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy

Current Urology Reports

Volumn 6, Issue 3, 2005, Pages 157-158

  Bruder, Jan M ^a  

^a University of Texas Health Science Center   (United States)

Author keywords

Alendronate; Bone Mineral Density; Oral Bisphosphonate; Osteoporosis; Pamidronate

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE;

BONE DENSITY; CALCIUM INTAKE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG MONITORING; HUMAN; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHOTON ABSORPTIOMETRY; PROSTATE TUMOR; REVIEW; UROLOGY;

ABSORPTIOMETRY, PHOTON; ADMINISTRATION, ORAL; ANDROGEN ANTAGONISTS; BONE DENSITY; CALCIUM, DIETARY; DIPHOSPHONATES; DRUG MONITORING; FRACTURES, SPONTANEOUS; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS; UROLOGY;

EID: 32844474818     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-005-0001-x     Document Type: Note

References (9)

1. Mittan D, Miller E, Basler J, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656–3661. DOI: 10.1210/jc.87.8.3656
2. Smith MR, McGovern FJ, Zeitman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948–955. DOI: 10.1056/NEJMoa010845
3. Smith MR, Eastham J, Gleason DM, et al.: Randomized, controlled trial of zolendronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008–2012. DOI: 10.1097/01.ju.0000063820.94994.95
4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154–164. DOI: 10.1056/NEJMoa041943
5. The WHO Study Group: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Geneva: World Health Organization; 1994.
6. Faulkner KG, Stetten E, Miller P: Discordance in patient classification using T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 1999, 2:343–350. DOI: 10.1385/JCD:2:3:343
7. Welch MD, Bruder JM: Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. J Bone Miner Res 2002, 17:S411.
8. Faulkner KG, Orwoll E: Implications in the use of T-scores for the diagnosis of osteoporosis in men. J Clin Densitom 2002, 5:87–93. DOI: 10.1385/JCD:5:1:087
9. Orwoll E, Ettinger M, Stuart W, et al.: Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610. DOI: 10.1056/NEJM200008313430902